Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BMS-582949

Generic Name: BMS-582949

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆N_₆O_₂

CAS Number: 623152-17-0

Unique Ingredient Identifier: CR743OME9E

Overview

BMS-582949 has been investigated for the treatment of Psoriasis.

Background

BMS-582949 has been investigated for the treatment of Psoriasis.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

PoC in Rheumatoid Arthritis With Methotrexate

Phase 2

Completed

Posted: 2008/01/31

Sponsor:Bristol-Myers Squibb

ID:NCT00605735

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

Phase 2

Completed

Posted: 2007/12/11

Sponsor:Bristol-Myers Squibb

ID:NCT00570752

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Posted: 2006/11/15

Sponsor:Bristol-Myers Squibb

ID:NCT00399906

Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background

Phase 1

Completed

Posted: 2005/09/13

Sponsor:Bristol-Myers Squibb

ID:NCT00162292

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy